Goldman Sachs Group Inc. Reduces Stock Position in Kyverna Therapeutics, Inc. $KYTX

Goldman Sachs Group Inc. lessened its stake in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) by 7.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 104,460 shares of the company’s stock after selling 9,014 shares during the quarter. Goldman Sachs Group Inc. owned approximately 0.24% of Kyverna Therapeutics worth $202,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Squarepoint Ops LLC purchased a new stake in Kyverna Therapeutics during the 4th quarter worth about $43,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Kyverna Therapeutics by 53.7% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,288 shares of the company’s stock worth $53,000 after purchasing an additional 4,990 shares in the last quarter. Rhumbline Advisers increased its position in Kyverna Therapeutics by 22.0% during the 1st quarter. Rhumbline Advisers now owns 31,614 shares of the company’s stock worth $61,000 after purchasing an additional 5,694 shares in the last quarter. Bank of America Corp DE increased its position in Kyverna Therapeutics by 41.6% during the 4th quarter. Bank of America Corp DE now owns 21,788 shares of the company’s stock worth $81,000 after purchasing an additional 6,400 shares in the last quarter. Finally, Nuveen LLC purchased a new stake in Kyverna Therapeutics during the 1st quarter worth about $92,000. Hedge funds and other institutional investors own 18.08% of the company’s stock.

Kyverna Therapeutics Stock Performance

Shares of NASDAQ:KYTX opened at $6.10 on Monday. Kyverna Therapeutics, Inc. has a 1 year low of $1.78 and a 1 year high of $7.20. The stock has a market capitalization of $263.83 million, a P/E ratio of -1.66 and a beta of 3.07. The stock has a 50-day simple moving average of $4.06 and a 200-day simple moving average of $3.10.

Kyverna Therapeutics (NASDAQ:KYTX) last issued its earnings results on Tuesday, August 12th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.03. Analysts predict that Kyverna Therapeutics, Inc. will post -3.29 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have commented on KYTX shares. William Blair started coverage on Kyverna Therapeutics in a report on Wednesday, August 20th. They issued an “outperform” rating for the company. HC Wainwright lifted their price target on Kyverna Therapeutics from $5.00 to $10.00 and gave the company a “buy” rating in a report on Friday, August 29th. One analyst has rated the stock with a Strong Buy rating and six have issued a Buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $16.60.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.